Comparative Expression Analysis of Somatostatin Receptor Subtypes in Human Neuroendocrine Tumors Using Two Sets of New Monoclonal Antibodies Abstract #446

Introduction: Expression of somatostatin receptor subtypes (sstr) is required for the successful use of somatostatin analogues (SSA) in the treatment of neuroendocrine tumors (NET). Reliable detection of sstr could improve the selection of SSA treatment. Rabbit and mouse monoclonal antibodies (mAbs) were recently developed independently in Jena and Basel.
Aim(s): To evaluate the utility of two sets of mAbs against sstr1, 2, 3, 5 in formaldehyde-fixed NETs.
Materials and methods: Newly generated mouse and rabbit mAbs specific to human sstr1, 2, 3, 5 were characterized with transfected HEK293 cells and normal pancreatic tissue. Comparative analysis of rabbit v. mouse mAbs was also conducted by immunostaining a tissue microarray (TMA) of 75 NET cores. Scoring was done with image analysis algorithms (Aperio).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Herbert Schmid

To read results and conclusion, please login ...

Further abstracts you may be interested in

#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#791 Quantification of Somatostatin Receptor Subtypes Using In Vivo PET/CT-Data, Ex Vivo Conventional Immunohistochemistry and Automated Digitized Analysis by Definiens XD Image Software
Introduction: Diagnostics and therapy of NET are significantly influenced by their somatostatin receptor (SSTR) status. Immunohistochemistry (IHC) of SSTR performed by pathologists is a time-consuming and cost-intensive procedure.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr. med. Daniel Kaemmerer
Keywords: SSTR
#183 Immunhistochemical Expression of Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors Using IRS- and Her2-scoring Scheme
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are known for an overexpression of somatostatin receptors (SSTR). This finding has already gained importance in diagnostics and therapy of NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Luisa Peter
Authors: Peter L, Kaemmerer D, Lupp A, Saenger J, ...
#1038 Co-Expression of Somatostatin and CXCR4 Receptors as Targets for Diagnostics and Treatment in Intestinal Neuroendocrine Neoplasms.
Introduction: Somatostatin receptors (SSTR) are widely distributed in well-differentiated neuroendocrine tumors (NET) and serve as primary targets for diagnostics and treatment. An overexpression of the chemokine receptor CXCR4, in contrast, is considered to be present mainly in highly proliferative and advanced carcinomas.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Daniel Kaemmerer
Keywords: sstr
#1162 Comparative Marker Assessment in Small Cell Lung Cancer with Good and Poor Prognosis
Introduction: Small cell lung cancers (SCLC) are highly aggressive and poorly differentiated neuroendocrine neoplasms which comprise ̴̴̴15 % of all lung malignancies.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Lydia Schmidt